AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18294411
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 microg kg(‐1) over 10 min at anaesthesia induction followed by 0.4‐0.8 microg kg(‐1) h(‐1) infusion during maintenance
Trial: 18294411
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 microg kg(‐1) over 1 min at anaesthesia induction followed by 0.2‐0.4 microg kg(‐1) min(‐1) infusion during maintenance
Trial: 16274834
Drug: ISIS 14803
RxNorm normalized name: ISIS 14803
DrugBank: ISIS 14803 (DB05803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 14803 (0.5-3 mg/kg, thrice weekly for 4 weeks)
Trial: 11030202
Drug: 1-week course
RxNorm normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week course of oral prednisolone (PSL, 0.5 mg/kg)
Trial: 11030202
Drug: 2-week course
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week course of oral prednisolone (PSL, 0.5 mg/kg)
Trial: 3818148
Drug: Pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 50 mg plus Ranitidine 150 mg
Trial: 29972003
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (before and after treatment)
Trial: 21280296
Drug: Antistax at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antistax at a daily dose of 360 mg
Trial: 21280296
Drug: Antistax at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antistax at a daily dose of 720 mg
Trial: 16104439
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg isobaric ropivacaine
Trial: 16104439
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg isobaric ropivacaine plus 25 microg fentanyl
Trial: 12005465
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of standard parenteral nutrition (1.5-liter HPN formula, infused over 10 hours, approximately 25 kcal/kg/d with 30% lipid and 1.0 to 1.5 g/kg/d of protein)
Trial: 12005465
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of standard parenteral nutrition
Trial: 7770303
Drug: Dexamethasone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.15 mg/kg every 6 hours for 4 days)
Trial: 2180230
Drug: Live Shigella
RxNorm normalized name: Shigella dysenteriae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live Shigella flexneri 2a and Shigella sonnei vaccine candidate strains with two virulence‐reducing markers
Trial: 2180230
Drug: Ultrasonic lysates
RxNorm normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic lysates of vaccine candidate strains
Trial: 31977888
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation (CCR) 3 times a week for 8 weeks plus neurologic music therapy (NMT) techniques, performed 3 times a week for 8 weeks.
Trial: 27405522
Drug: Mentalization-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based treatment in groups for 1 year
Trial: 27405522
Drug: Mentalization-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based treatment in groups
Trial: 25055821
Drug: Prucalopride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride (2 mg once daily) for 32 weeks
Trial: 19505393
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose sublingual‐swallow therapy (SLIT)
Trial: 12410756
Drug: Desmopressin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin therapy (with or without anticholinergic agents)
Trial: 12410756
Drug: NDE group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDE group (therapy‐resistant enuresis)
Trial: 29650683
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m2 days 1, 4, and 7
Trial: 18928735
Drug: Comprehensive education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive education about the disease, drug therapy, diet, and telephonic strengthening
Trial: 8607955
Drug: Antibiotic ear
RxNorm normalized name: Antibiotic Ear
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic ear drops (suspension of polymyxin B sulfate, neomycin sulfate, and hydrocortisone)
Trial: 6208248
Drug: neomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neomycin (1 g/l) + bacitracin (50,000 IU/l) + clindamycin (900 mg/l)
Trial: 6208248
Drug: mezlocillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mezlocillin (4 g) + oxacillin (2 g) intravenously
Trial: 6208248
Drug: no antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no antibiotics
Trial: 29913743
Drug: Standard Gynecological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Gynecological Treatment + Mensendieck Somatocognitive Therapy (MSCT)
Trial: 29913743
Drug: Standard Gynecological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Gynecological Treatment (STGT)
Trial: 18337147
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (MgSO4) 0.1 mg/l (4g)
Trial: 12056708
Drug: Eniluracil/5-fluorouracil (5-FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eniluracil/5-fluorouracil (5-FU) regimen: 5-FU 1 mg/m2 twice daily + eniluracil 10 mg/m2 twice daily for 28 days
Trial: 10078606
Drug: TA-GW vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-GW vaccine (300 microg)
Trial: 10078606
Drug: TA-GW vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-GW vaccine (0, 3, 30 microg)
Trial: 8575575
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg.day‐1 for 4 days)
Trial: 8575575
Drug: OKY‐046 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKY‐046 (400 mg.day‐1 for 4 days)
Trial: 30542740
Drug: Hydrogen gas
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen gas inhalation for 3 hours/day at home
Trial: 26825258
Drug: Drospirenone-containing combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone-containing combined oral contraceptives (DRSP)
Trial: 22047681
Drug: L-carnitine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine 4 g/day + Celecoxib 300 mg/day
Trial: 22047681
Drug: L-carnitine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine 4 g/day + celecoxib 300 mg/day + megestrol acetate 320 mg/day
Trial: 16053010
Drug: Daily renal
RxNorm normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily renal multivitamin containing folate (FA), vitamin B6 and B12 (5 mg, 10 mg and 0.4 mg respectively)
Trial: 16053010
Drug: Supraphysiological daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiological daily doses (15 mg, 100 mg and 1 mg)
Trial: 7491880
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g fat
Trial: 7491880
Drug: 80 g
RxNorm normalized name: PEG-80 GLYCERYL COCOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g fat
Trial: 7491880
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g fat plus 50 g fructose
Trial: 7491880
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (36 mg, or 120,000 U retinol)
Trial: 1828420
Drug: Amlodipine 1.25
RxNorm normalized name: levamlodipine 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 1.25 mg
Trial: 1828420
Drug: All amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All amlodipine doses
Trial: 1828420
Drug: Amlodipine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (all doses)
Trial: 6791200
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg haloperidol IM
Trial: 22191384
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone extract (daily oral intake)
Trial: 18214607
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (5,000 IU) administered subcutaneously 20 to 30 min before ERCP
Trial: 18214607
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution 0.5 ml) administered subcutaneously 20 to 30 min before ERCP
Trial: 18214607
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution 0.5 ml)
Trial: 15845568
Drug: Chemoradiotherapy (CRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (CRT) with concurrent carboplatin 30 mg/m² per fraction up to the first 20 fractions.
Trial: 12826150
Drug: Simulect (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulect (20 mg, 30 minutes before reperfusion and 4 days after transplantation) and steroids
Trial: 10582540
Drug: Verapamil (VER)
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil (VER) administered acutely
Trial: 10582540
Drug: Verapamil (VER)
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil (VER) administered intravenously (IV)
Trial: 10582540
Drug: Different oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different oral formulations of Verapamil (VER)
Trial: 7225473
Drug: Sublingual exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual exposure to allergens
Trial: 29649997
Drug: Coaching Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coaching Group (CoachG; feedback on daily steps, MVPA, total EE with need supportive coaching)
Trial: 27646843
Drug: Ricolinostat 160
RxNorm normalized name: Ricolinostat
DrugBank: Ricolinostat (DB12376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ricolinostat 160 mg once daily on days 1–21 of a 28 day cycle, in combination with lenalidomide 25 mg and dexamethasone 40 mg.
Trial: 18570844
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg diclofenac anal suppository after surgery
Trial: 797543
Drug: Active corticosteroid
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active corticosteroid comparison drug
Trial: 30781962
Drug: Postoperative continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative continuous lavage (irrigation with saline or another solution over 24-48 hours)
Trial: 27796035
Drug: Enhanced medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced medication plan with graphical and textual information on drug handling
Trial: 27796035
Drug: Simple medication
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple medication plan with standard information
Trial: 23273975
Drug: Glyburide therapy
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide therapy (dose of 3.3±2.1 mg/day for R230C vs 6.3±5 mg/day for R230R)
Trial: 11290867
Drug: Ifosfamide 1500
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide 1500 mg/m2 in 1000 ml saline infused over 60 min, mesna 20% of total dose of ifosfamide in three doses for 3 days, mitoxantrone 12 mg/m2 on day 1; treatment repeated every 4 weeks for up to six cycles.
Trial: 2682243
Drug: Intravenous desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous desmopressin (0.3 microgram per kilogram of body weight)
Trial: 31783161
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) mediated antimicrobial photodynamic therapy (aPDT) along with scaling and root planing (SRP)
Trial: 31293563
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose 27,476 IU
Trial: 24348029
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body vibration (WBV) at 30 Hz and 3.2 g for 5 minutes, three times per week for 6 months
Trial: 22186118
Drug: Mildronate 100
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mildronate 100 mg
Trial: 22186118
Drug: Mildronate 300
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mildronate 300 mg
Trial: 22186118
Drug: Mildronate 1000
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mildronate 1000 mg
Trial: 22186118
Drug: Mildronate 3000
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mildronate 3000 mg
Trial: 16504757
Drug: Concomitant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemoradiotherapy (Arm A): 500 mg/m2 5-fluorouracil, 12 mg/m2 mitoxantrone, and 500 mg/m2 cyclophosphamide with concomitant radiotherapy (50 Gy +/- 10-20-Gy boost)
Trial: 16504757
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant chemotherapy followed by radiotherapy (Arm B): 500 mg/m2 5-fluorouracil, 60 mg/m2 epirubicin, and 500 mg/m2 cyclophosphamide with subsequent radiotherapy
Trial: 11967036
Drug: AM3 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM3 (3 g/day) for 30 consecutive days starting 15 days prior to the first vaccine dose
Trial: 11967036
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 g/day) for 30 consecutive days starting 15 days prior to the first vaccine dose
Trial: 10754365
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg i.v. erythromycin
Trial: 6788400
Drug: i.v. encainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. encainide 75 mg
Trial: 6788400
Drug: oral encainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral encainide 75 mg
Trial: 29193211
Drug: TXA 1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA 1g intravenous bolus followed by continuous infusion of TXA 1g over 8 hours
Trial: 24993769
Drug: Noradrenaline (0-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline (0-12 µg/min)
Trial: 24993769
Drug: Hydrocortisone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (50 mg intravenous bolus six-hourly)
Trial: 20032699
Drug: Dexmedetomidine (0.6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.6, 1.2, 2.4 ng/ml)
Trial: 20032699
Drug: Propofol (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1, 2, 4 microg/ml)
Trial: 15957828
Drug: Purified Xuefu
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified Xuefu Capsule (PXC) with conventional western medicine
Trial: 9872814
Drug: Inhaled PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhaled PGE2 (100 microgram)
Trial: 7312535
Drug: Biological content
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological content presented at variable rates
Trial: 31995813
Drug: Modafinil (single-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (single-dose, 200 mg)
Trial: 31283407
Drug: Myeloid-style consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloid-style consolidation chemotherapy (ADE and MAE)
Trial: 31283407
Drug: Lymphoid-style consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphoid-style consolidation chemotherapy (IB)
Trial: 24126178
Drug: Flaxseed (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (30 g of milled flaxseed daily for 6 months)
Trial: 24126178
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily ingestion of placebo for 6 months)
Trial: 12445026
Drug: V11294A (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V11294A (300 mg)
Trial: 7009887
Drug: Trimethoprim-sulfamethoxazole combination
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole combination
Trial: 27050206
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy plus chemotherapy (procarbazine, CCNU, and vincristine)
Trial: 23688162
Drug: 0.5% nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% nifedipine cream
Trial: 21173378
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by either surgery or chemoradiotherapy
Trial: 17368645
Drug: Glucose-boosted saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-boosted saline solution (5% glucose)
Trial: 16379581
Drug: Traxoprodil (CP-101,606)
RxNorm normalized name: CP
DrugBank: Traxoprodil (DB18795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traxoprodil (CP-101,606) 72-hour infusion
Trial: 11917251
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 1% aqueous extract of Fucus vesiculosus, applied twice daily for five weeks
Trial: 9637644
Drug: 5 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 microg/kg oral clonidine (clonidine group, n=25)
Trial: 28421779
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine (0.5 g/kg/day)
Trial: 26329749
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg/day for 5 years
Trial: 26329749
Drug: Telbivudine after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine after lamivudine 100 mg/day for 2 years
Trial: 21545506
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg cyclosporin emulsion once daily (group A)
Trial: 21545506
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg cyclosporin emulsion twice daily (group B)
Trial: 18840643
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium intake (670-2003 mg/d)
Trial: 18840643
Drug: Other serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other serum hormone levels
Trial: 18840643
Drug: Biomarkers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarkers of bone metabolism, habitual physical activity, habitual calcium intake, and physical fitness
Trial: 9188109
Drug: 0.2 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg.kg‐1 nasally
Trial: 9188109
Drug: 0.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg.kg‐1 rectally
Trial: 9188109
Drug: 0.2 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg.kg‐1 sublingually
Trial: 9188109
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (nasal, rectal, sublingual)
Trial: 2964215
Drug: Sufentanil (0.05-0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.05-0.15 μg/kg)
Trial: 2964215
Drug: Diazepam (0.05-0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.05-0.15 mg/kg)
Trial: 26784973
Drug: Resveratrol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 1.5 g daily for 6 months
Trial: 23731362
Drug: 1,200-mg oral-N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200-mg oral-N-acetylcysteine (NAC) two times a day, starting 48 hours before and up to 72 hours after surgery
Trial: 23731362
Drug: 1,200-mg oral-N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200-mg oral-N-acetylcysteine (NAC)
Trial: 17011327
Drug: Triptorelin 3.75
RxNorm normalized name: triptorelin 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 3.75 mg every 4 weeks (group 1)
Trial: 15233305
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of drugs (O, R, H, Z)
Trial: 11198725
Drug: Placebo (demulcent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (demulcent lozenge without active drug)